Masimo Corp is primarily active in the medical device industry.

The main competitors of Masimo Corp in the market include companies such as Philips Healthcare, Nihon Kohden Corporation, and Smiths Medical.

Masimo Corp is a leading global medical technology company specializing in noninvasive patient monitoring. Founded in 1989 by Joe Kiani, the company has a rich history of innovation and advancements in the healthcare industry. Masimo Corp's core business revolves around developing and manufacturing advanced monitoring technologies, including pulse oximeters and signal extraction technology. With its commitment to improving patient outcomes and reducing healthcare costs, Masimo Corp has revolutionized the way healthcare professionals monitor patients' vital signs. Today, it is recognized as a trusted name in the medical device industry, providing innovative solutions that enhance patient care and safety worldwide.

Masimo Corp has achieved several significant milestones. Some noteworthy accomplishments include the development of breakthrough technologies in noninvasive patient monitoring, such as SET® pulse oximetry. The company has also received numerous awards and recognition for its innovative products and contributions to the healthcare industry. Masimo Corp has successfully expanded its global presence and formed strategic partnerships with leading healthcare organizations worldwide. Additionally, the company has consistently shown strong financial performance and steady revenue growth over the years. Overall, Masimo Corp continues to make strides in advancing patient care through its cutting-edge technologies and industry leadership.

Masimo Corp is primarily present in various countries and regions across the globe. Some notable markets where the company operates include the United States, European countries like Germany, France, and the United Kingdom, as well as Asian countries including Japan and China. Masimo Corp's global presence enables it to provide its innovative healthcare solutions, including noninvasive patient monitoring technologies, to healthcare facilities and professionals worldwide.

Masimo Corp represents a strong commitment to improving patient outcomes and reducing healthcare costs through innovative medical technologies. The company values include a dedication to patient safety, quality, and continuous improvement. Masimo's corporate philosophy revolves around providing noninvasive monitoring solutions that enable clinicians to make more informed decisions, enhance patient care, and optimize workflows. By combining advanced sensor and signal processing technologies, Masimo Corp strives to address the evolving needs of the medical community. The company's focus on research and development, as well as collaboration with healthcare professionals, reinforces its commitment to pioneering advancements in medical monitoring to benefit patients worldwide.

Analysts currently set an average price target of 180,21 USD for the Masimo stock (median: 183,60 USD), implying +0,1 % versus the latest price. The consensus is based on 16 analyst ratings.

Masimo Analytikerens Kursmål 2026

15 analysts currently rate the Masimo stock: 7 recommend buying, 8 holding and 0 selling. For 2026, analysts expect Masimo to generate revenue of 1,63 Mrd. USD and earnings per share of 5,97 USD.

Masimo Analytikerens Kursmål 2026

Converted at the current exchange rate, the Masimo share trades at 155,32 EUR (179,95 USD).

The Masimo share (MASI) is listed on 8 stock exchanges, including: NYSE (MASI), NASDAQ (MASI), Frankfurt (3M4.F), München (3M4.MU), Düsseldorf (3M4.DU), London (0JZ2.L), London (0JZ2.L), SIX (Zürich) (3M4.SW).

Masimo Corporation is a leading provider of medical diagnostic and monitoring technologies that aim to make patient care safer and more effective. The company is headquartered in California and operates offices worldwide. Masimo's business model can be roughly divided into three areas: 1. Products and technologies Masimo offers a wide range of medical devices and technologies, including pulse oximeters for monitoring oxygen saturation in the blood, capnographs for monitoring end-tidal carbon dioxide concentration, as well as patient monitors and control systems. A highlight is Masimo's Signal Extraction Technology (SET), which is used in almost all of the company's products. SET uses a special algorithm to filter signals from skin color, movement, and other external sources of interference, allowing for accurate measurements. Additionally, Masimo has developed other innovative technologies, such as automatic measurement of hemoglobin levels, which can lead to improved patient outcomes. 2. Services Masimo also offers various services, such as installation, training, and technical support for its products. Furthermore, the company has entered into partnerships with other companies such as Apple and Philips to jointly develop innovative solutions for patient monitoring. 3. Research and development Masimo invests heavily in the research and development of new products and technologies. The company has filed numerous patents and successfully implemented them. By collaborating with clinics and universities, Masimo ensures that its products have informative features and high quality that meet the needs of patients and medical professionals. Overall, Masimo's business model is designed to make healthcare safer and more effective by developing innovative products and technologies, and by providing services and support to its customers. The wide range of products and technologies, as well as the investments in research and development, indicate that Masimo will continue to play an important role in the medical industry in the future.

forventet-omsætningen for Masimo er 1,63 Mrd. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for Masimo er 323,74 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Masimo er i øjeblikket 30,13. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Masimo-aktien.

Pris-til-salgs-forholdet (P/S) for Masimo er i øjeblikket 5,97. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Masimo-aktien.

AlleAktien-kvalitetsscore for Masimo er 4/10.

ISIN for Masimo er US5747951003. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Masimo er 578074. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Masimo er MASI. Tickersymbolet bruges til at handle Masimo-aktier på børsen.

Dividendeudbytteprocenten for Masimo er i øjeblikket 0,56 %.

Masimo har udbetalt dividende hvert år i de seneste 0 år.

Masimo er klassificeret i sektoren 'Sundhed'.

For at modtage den seneste dividende fra Masimo fra på 1 USD, skulle du have aktien i din portefølje før ex-datoen den .

Sidste dividende blev udbetalt den .

Dividenderne fra Masimo udloddes i USD.